[
  {
    "ts": "2025-09-12T12:33:25+00:00",
    "headline": "Maia’s NSCLC immunotherapy secures Phase II efficacy win",
    "summary": "The biotech is now running a Phase II expansion study to better evaluate the long-term benefits of ateganosine in third-line NSCLC.",
    "url": "https://www.clinicaltrialsarena.com/news/maia-biotechnology-ateganosine-phase-ii-third-line-nsclc/",
    "source": "Clinical Trials Arena",
    "provider": "yfinance",
    "raw": {
      "id": "7afad917-6c5a-3e43-96b6-b7834b416270",
      "content": {
        "id": "7afad917-6c5a-3e43-96b6-b7834b416270",
        "contentType": "STORY",
        "title": "Maia’s NSCLC immunotherapy secures Phase II efficacy win",
        "description": "",
        "summary": "The biotech is now running a Phase II expansion study to better evaluate the long-term benefits of ateganosine in third-line NSCLC.",
        "pubDate": "2025-09-12T12:33:25Z",
        "displayTime": "2025-09-12T12:33:25Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/clinical_trials_arena_396/7006d3f0cf3c02848c2063abfa1f29c6",
          "originalWidth": 2560,
          "originalHeight": 1600,
          "caption": "Maia Biotechnology's telomerase modifier",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/GmEqWyn33oIJqRvCgFyA3w--~B/aD0xNjAwO3c9MjU2MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/clinical_trials_arena_396/7006d3f0cf3c02848c2063abfa1f29c6.cf.webp",
              "width": 2560,
              "height": 1600,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/t4TaFG01BaTyuEhapAOFrg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/clinical_trials_arena_396/7006d3f0cf3c02848c2063abfa1f29c6.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Clinical Trials Arena",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.clinicaltrialsarena.com/news/maia-biotechnology-ateganosine-phase-ii-third-line-nsclc/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/maia-nsclc-immunotherapy-secures-phase-123325265.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MAIA"
            },
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]